Compare Stocks: SGMT, SLS, VRDN, and CDNA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$48.93 -1.4%	$39.84	$12.37 ▼ $53.67	$2.53B	2.43	862,901 shs	143,331 shs
SGMT Sagimet Biosciences	$10.76 -2.1%	$8.52	$4.50 ▼ $11.24	$668.84M	3.45	1.17 million shs	285,222 shs
SLS SELLAS Life Sciences Group	$14.17 +0.0%	$12.75	$1.39 ▼ $15.88	$2.86B	2.52	8.20 million shs	2.45 million shs
VRDN Viridian Therapeutics	$23.08 +1.3%	$20.90	$13.18 ▼ $34.29	$2.62B	0.97	2.13 million shs	178,147 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	+1.29%	-2.67%	+3.66%	+114.53%	+258.12%
SGMT Sagimet Biosciences	+4.67%	+1.20%	+53.71%	+55.67%	+49.32%
SLS SELLAS Life Sciences Group	+7.11%	+3.13%	+26.20%	+56.64%	+673.77%
VRDN Viridian Therapeutics	-1.09%	-6.10%	+17.97%	+37.48%	+19.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$48.93 -1.4%	$39.84	$12.37 ▼ $53.67	$2.53B	2.43	862,901 shs	143,331 shs
SGMT Sagimet Biosciences	$10.76 -2.1%	$8.52	$4.50 ▼ $11.24	$668.84M	3.45	1.17 million shs	285,222 shs
SLS SELLAS Life Sciences Group	$14.17 +0.0%	$12.75	$1.39 ▼ $15.88	$2.86B	2.52	8.20 million shs	2.45 million shs
VRDN Viridian Therapeutics	$23.08 +1.3%	$20.90	$13.18 ▼ $34.29	$2.62B	0.97	2.13 million shs	178,147 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	+1.29%	-2.67%	+3.66%	+114.53%	+258.12%
SGMT Sagimet Biosciences	+4.67%	+1.20%	+53.71%	+55.67%	+49.32%
SLS SELLAS Life Sciences Group	+7.11%	+3.13%	+26.20%	+56.64%	+673.77%
VRDN Viridian Therapeutics	-1.09%	-6.10%	+17.97%	+37.48%	+19.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDNA CareDx	2.63	Moderate Buy	$51.20	3.23% Upside
SGMT Sagimet Biosciences	2.60	Moderate Buy	$29.17	165.39% Upside
SLS SELLAS Life Sciences Group	2.33	Hold	$10.00	-29.38% Downside
VRDN Viridian Therapeutics	2.85	Moderate Buy	$38.54	69.18% Upside

Current Analyst Ratings Breakdown

Latest SGMT, SLS, VRDN, and CDNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	CDNA CareDx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$65.00
9/2/2026	CDNA CareDx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$65.00
8/25/2026	SGMT Sagimet Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$29.00
8/14/2026	SGMT Sagimet Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/14/2026	SGMT Sagimet Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$12.00 ➝ $29.00
8/13/2026	CDNA CareDx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C)
8/12/2026	SLS SELLAS Life Sciences Group	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	SGMT Sagimet Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$49.00 ➝ $56.00
8/7/2026	VRDN Viridian Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$35.00 ➝ $36.00
8/7/2026	VRDN Viridian Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $39.00
8/6/2026	CDNA CareDx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDNA CareDx	$379.80M	6.76	$0.01 per share	7,518.35	$8.23 per share	6.03
SGMT Sagimet Biosciences	$2M	341.57	N/A	N/A	$4.12 per share	2.67
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	$0.68 per share	N/A
VRDN Viridian Therapeutics	$70.85M	36.43	N/A	N/A	$4.98 per share	4.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDNA CareDx	-$21.35M	$2.07	23.96	78.73	N/A	24.23%	2.87%	2.17%	11/3/2026 (Estimated)
SGMT Sagimet Biosciences	-$51.04M	-$1.28	N/A	N/A	N/A	N/A	-31.96%	-30.57%	11/12/2026 (Estimated)
SLS SELLAS Life Sciences Group	-$26.86M	-$0.21	N/A	N/A	N/A	N/A	-35.91%	-33.34%	11/11/2026 (Estimated)
VRDN Viridian Therapeutics	-$342.60M	-$3.37	N/A	N/A	N/A	-505.86%	-72.97%	-42.80%	11/4/2026 (Estimated)

Latest SGMT, SLS, VRDN, and CDNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	SGMT Sagimet Biosciences	-$0.2510	-$0.26	-$0.0090	-$0.26	N/A	N/A
8/11/2026	Q2 2026	SLS SELLAS Life Sciences Group	-$0.0450	-$0.05	-$0.0050	-$0.05	N/A	N/A
8/6/2026	Q2 2026	VRDN Viridian Therapeutics	-$1.03	-$1.05	-$0.02	-$1.05	$0.06 million	$0.28 million
7/30/2026	Q2 2026	CDNA CareDx	$0.2321	$0.37	+$0.1379	$2.07	$114.05 million	$131.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A
VRDN Viridian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDNA CareDx	N/A	4.58	4.51
SGMT Sagimet Biosciences	N/A	45.03	45.02
SLS SELLAS Life Sciences Group	N/A	18.83	18.83
VRDN Viridian Therapeutics	0.43	16.95	16.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDNA CareDx	N/A
SGMT Sagimet Biosciences	87.86%
SLS SELLAS Life Sciences Group	17.38%
VRDN Viridian Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CDNA CareDx	2.40%
SGMT Sagimet Biosciences	11.50%
SLS SELLAS Life Sciences Group	1.30%
VRDN Viridian Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDNA CareDx	740	51.73 million	50.49 million	Optionable
SGMT Sagimet Biosciences	8	62.16 million	55.01 million	Optionable
SLS SELLAS Life Sciences Group	10	201.95 million	199.32 million	Not Optionable
VRDN Viridian Therapeutics	50	113.29 million	110.57 million	Optionable

SGMT, SLS, VRDN, and CDNA Headlines

Recent News About These Companies

Velan Capital Investment Management LP Has $184,000 Stock Holdings in Viridian Therapeutics, Inc. $VRDN

September 3 at 5:51 AM | marketbeat.com

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 2 at 8:34 PM | finance.yahoo.com

The Manufacturers Life Insurance Company Takes $3.31 Million Position in Viridian Therapeutics, Inc. $VRDN

September 2 at 4:48 AM | marketbeat.com

Yiheng Capital Management L.P. Has $7.36 Million Holdings in Viridian Therapeutics, Inc. $VRDN

August 31 at 6:31 AM | marketbeat.com

Algert Global LLC Sells 81,762 Shares of Viridian Therapeutics, Inc. $VRDN

August 27, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)

August 26, 2026 | theglobeandmail.com

Elmind Capital LP Purchases Shares of 984,931 Viridian Therapeutics, Inc. $VRDN

August 26, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Makes New $25.31 Million Investment in Viridian Therapeutics, Inc. $VRDN

August 25, 2026 | marketbeat.com

Deutsche Bank AG Invests $8.87 Million in Viridian Therapeutics, Inc. $VRDN

August 24, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT) and Viridian Therapeutics (VRDN)

August 21, 2026 | theglobeandmail.com

Insider Selling: Viridian Therapeutics (NASDAQ:VRDN) Insider Sells 14,212 Shares

August 21, 2026 | insidertrades.com

260,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Blue Owl Capital Holdings LP

August 21, 2026 | marketbeat.com

Viridian Therapeutics (NASDAQ:VRDN) Insider Jennifer Tousignant Sells 14,212 Shares

August 20, 2026 | marketbeat.com

Handelsbanken Fonder AB Invests $834,000 in Viridian Therapeutics, Inc. $VRDN

August 20, 2026 | marketbeat.com

GSA Capital Partners LLP Invests $903,000 in Viridian Therapeutics, Inc. $VRDN

August 19, 2026 | marketbeat.com

93,414 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Merck & Co. Inc.

August 18, 2026 | marketbeat.com

1,175,906 Shares in Viridian Therapeutics, Inc. $VRDN Bought by Rice Hall James & Associates LLC

August 18, 2026 | marketbeat.com

Bank of America Corp DE Acquires 173,498 Shares of Viridian Therapeutics, Inc. $VRDN

August 18, 2026 | marketbeat.com

Viridian Therapeutics Inc VRDN

August 15, 2026 | morningstar.comM

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 11, 2026 | marketbeat.com

HC Wainwright Has Negative Forecast for VRDN Q3 Earnings

August 10, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT, SLS, VRDN, and CDNA Company Descriptions

CareDx NASDAQ:CDNA

$48.93 -0.67 (-1.35%)

As of 11:49 AM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Sagimet Biosciences NASDAQ:SGMT

$10.76 -0.23 (-2.11%)

As of 11:50 AM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

SELLAS Life Sciences Group NASDAQ:SLS

$14.16 +0.01 (+0.04%)

As of 11:50 AM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Viridian Therapeutics NASDAQ:VRDN

$23.08 +0.30 (+1.31%)

As of 11:50 AM Eastern

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SGMT, SLS, VRDN, and CDNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SGMT, SLS, VRDN, and CDNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SGMT, SLS, VRDN, and CDNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT, SLS, VRDN, and CDNA Company Descriptions

CareDx NASDAQ:CDNA

Sagimet Biosciences NASDAQ:SGMT

SELLAS Life Sciences Group NASDAQ:SLS

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SGMT, SLS, VRDN, and CDNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SGMT, SLS, VRDN, and CDNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SGMT, SLS, VRDN, and CDNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT, SLS, VRDN, and CDNA Company Descriptions

CareDx NASDAQ:CDNA

Sagimet Biosciences NASDAQ:SGMT

SELLAS Life Sciences Group NASDAQ:SLS

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools